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Abstract
Backgrounds
MicroRNAs (miRNA) are a class of non-protein-coding RNAs that have significant biological
and pathological functions. The importance of miRNAs as potential cancer diagnostic bio-
markers is gaining attention due to their influence in the regulation of cellular processes
such as cell differentiation, proliferation and apoptosis. The aim of this study was to identify
significant miRNAs from saliva as potential diagnostic biomarkers in the early diagnosis and
prognosis of head and neck squamous cell carcinoma (HNSCC).
Materials and methods
Five differentially expressed miRNAs (miR-7703, miR- let-7a-5p, miR- 345-5p, miR- 3928
and miR- 1470) were selected from Next Generation Sequencing (NGS) miRNA data gener-
ated from our previous study using saliva of 12 HNSCC patients and 12 healthy controls.
Their differential expressed miRNAs were subsequently validated by RT-qPCR using saliva
samples from healthy controls (n = 80) and HNSCC patients (n = 150). Total RNA was iso-
lated from 150 saliva samples of HNSCC patients and was transcripted into cDNA by Taq-
Man MicroRNA Reverse Transcription Kit. Using quantitative RT-PCR analysis, salivary
miRNAs were identified in HNSCC patients (n = 150) and healthy controlled cases (n = 80).
T-tests were used to compare the differences among the various clinical variants.
Results
On average 160 ng/μl was isolated from 500 μl of saliva. Overall, a good correlation
observed between the HNSCC and some of miRNAs expression levels. Salivary miR-let-
7a-5p (P<0.0001) and miR-3928 (P< 0.01) were significantly down regulated in saliva of
HNSCC patients relative to age and sex-matched healthy controls. A number of salivary
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miRNAs (miR-let-7a-5p and miR-3928) were correlated with lymph node metastasis (p =
0.003, p = 0.049) and tumour size (p = 0.01, p = 0.02), respectively. However, our prelimi-
nary analysis showed no significant differences in salivary miR-1470, miR-345-5p or miR-
7703 expression between patients and healthy controls. Most notably, our analysis showed
that salivary miR-let-7a-5p and miR-3928 expression levels have significant sensitivity and
specificity to distinguish between patients with HNSCC and healthy controls.
Conclusion
This study concluded that salivary miR-let-7a-5p and miR-3928 has the potential to be novel
non-invasive biomarkers for early detection and prognosis of HNSCC.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the fifth most frequent carcinoma in
men worldwide and includes tumours at various sites in the oral and upper aerodigestive tract
[1] with annual reported deaths of about 300,000 worldwide[2, 3]. The asymptomatic nature
of the tumour leads to late diagnosis, extensive lesions and potential metastasis even though
there may well be early salient potentially malignant disorders preceding [4]. Five year survival
remains a challenge with compromised prognosis and deaths [5]. Improved prognosis of
HNSCC requires early diagnosis through clinical examination and biomarker discovery [6].
Salivary biomarkers are ideal non-invasive diagnostic tool for diseases including cancer [4,
7–10]. The ease of collection and its non-invasive nature making salivary biomarkers a cheap
and reliable alternative when compared with traditional samples such as blood and tissue for
diagnosis and prognosis [11]. Furthermore, it is an ideal tool for large scale sample collection,
epidemiological screening and is relatively economical when it comes to long term monitoring
[12]. It has been reported that more than 3,000 species of RNA are expressed in saliva majority
of which are microRNAs (mRNAs) [13], and recent reports support its role in oral cancer pro-
gression and various cancers [14, 15, 16].
Since its discovery in 1993, miRNAs have been considered a novel regulator biomarker for
gene expression [17]. MiRNA is a small non-protein-coding RNA containing 19–24 nucleo-
tides that control the degradation and translation of RNA [18]. Evidence indicated that
miRNA has an important role in carcinogenesis [19, 20]. It has also been predicted that more
than one thousand miRNAs may be found in the human genome[20, 21]. Although multiple
mRNAs could be regulated by a single miRNA, few biological pathways are not influenced by
miRNAs. The aberrations in miRNA expression and their apparent pluripotent roles predict
that miRNA identification in oncogenesis might reveal networks or targets that are suitable for
cancer diagnostic markers or cancer therapy [20, 22]. In addition, it has been stated that there
is a unique miRNA biomarker for each cancer type [23]. For instance, correlation has previ-
ously been found between vascular invasion of HNSCC and miR-211 [24]. Moreover, miR-
184 and miR-21 have been identified to be oncogenic miRNAs in HNSCC [25]. From our ini-
tial study using next generation sequencing (Qiagen), a subset of five differentially expressed
miRNAs (miR-7703, miR- let-7a-5p, miR- 345-5p, miR- 3928 and miR- 1470) have been
selected (based on significant differential fold change) to determine their clinical utility as a
potential biomarker.
miR-let-7a-5p was found up-regulated in human prostate cancers and this miRNA accom-
panied the prostate oncogenic process [1]. However, a recent study demonstrated the down-
regulation of miR-let-7a-5p in a wide variety of neoplasms including colorectal carcinoma
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(CRC), breast cancer and lung cancer [26, 27]. miR-3928 has been demonstrated to be induced
by ionizing radiations in HeLa cells and targeted the endoribonuclease Dicer [28]. miR-345-5p
was shown to be expressed at substantially lower levels among the 34 predicted cytidine deami-
nase (CDA) associated miRNAs [29].
Materials and methods
Participants
Unstimulated whole saliva was collected before surgery from patients attended the Gold Coast
University Hospital (GCUH) in Gold Coast, Queensland with HNSCC (n = 150) at different
stages of the disease, from different sites (glottis, buccal sulcus, buccal mucosa, tongue, and
floor of the mouth (FOM). Similarly, whole saliva samples were collected from healthy controls
(n = 80) without a history of any malignancy, and who had good oral hygiene. In addition to
verbal, written informed consent obtained from all participants. Samples collected from a
period of December 1, 2015, to May 30, 2018, from the GCUH. HNSCC were classified accord-
ing to the extent or size of tumour (T), spread to the regional lymph nodes (N) and the pres-
ence or absence of metastasis (M) according to TNM classification (American Joint
Committee on Cancer) [30]. The clinical demographic data of all participants are listed in
Table 1. This study was approved by HREC of Griffith University (GU Ref No: 2015/766) and
Gold Coast University Hospital (HREC/15/QGC/223), Queensland, Australia.
Saliva collection
Whole saliva from participants were collected in 50-mL sterile falcon tube between 6 am to 11
am, as previously described [31, 32]. Participants were asked to refrain from eating, drinking,
any oral hygiene procedures. Five minutes prior to sample collection, participants were asked
to swish their mouth gently with sterile water, provided, to minimize contamination five min-
utes before sample collection. Participants were seated upright comfortably on a chair and
asked to spit into a 50-mL RNA/DNA free Falcon tube kept on a tray with ice. A maximum of
8 mL of whole saliva was collected from each subject within a duration of 20–30 min. Samples
were immediately stored in dry ice and sent for processing in the laboratory.
Salivary RNA extraction
RNeasy kit (Qiagen, Valencia, CA, USA) was used according to the manufacturer’s protocol to
extract total RNA from the collected saliva for each subject (440μl). Spectrophotometer (Nano-
Drop, ND2000; Wilmington, DE, USA) was used to validate the purification and quantifica-
tion of the isolated RNA.
Reverse transcription
Complementary DNA was generated via a miRNA reverse transcription kit (Origene, HP)
using total RNA (10–50 ng). The10-μl RT reaction mixture contained 1 to 2μg of total RNA,
1 μl of poly A tailing buffer, 1 μl of mM ATP, 1 μl of Poly (A) polymerase and adjusted by
molecular water. The polyadenylation reaction continued at 37˚C for 2 hours. 1μl of oligo dT
primer was then added to the tube, incubated at 70˚C for 5 minutes and placed in dry ice for 2
minutes. For final cDNA synthesis 4 μl of 5X MMLV buffer was added, then incubation at
42˚C for 1 hour, 95˚ for 5 minutes and then placed in dry ice. The reaction mixture was diluted
with 200μl nuclease- free water and kept at -20˚C for real-time quantitative polymerase chain
reaction (RT-qPCR).
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Real-time quantitative polymerase chain reaction
To evaluate miRNA, candidates from previous studies RT-qPCR, were analysed. RT-qPCR
processing of the miRNAs used specific forward and universal reverse primers based on the
manufacture’s protocol (Origene). All primers used in this study are mentioned in Table 2.
PCR amplicons were investigated by SYBR Green using the level of fluorescence emitted.
Reactions were performed in triplicate with cycling conditions as follows: 95˚C for 30 seconds
then 95˚C for 15 seconds, 55˚C for 10 seconds, and 72˚C for 30 seconds, repeated 42 times.
The melt curve analysis was set to validate the expected generation of the PCR product. The
setting was 60.0 to 95.0˚C at increments of 0.5˚C for 0.05 minutes. The Ct values were< 35. A
non-template control (NTC) was used as a negative control. Quant Studio 6 flex (Applied Bio-
systems) was used to carry out the RT-qPCR reactions and Δct was calculated and normalized
using housekeeping miRNA-16.
Statistical analyses
All data analysis was performed using Prism software, version 6. Samples were treated as nor-
mal and progressive HNSCC. Data normalized threshold cycle number ΔCt, where ΔCt = [Ct
Table 1. Demographic and clinical characteristics of HNSCC patients.
Characteristic HNSCC 150 (%) Control 80 (%) P value
Sex
Male 90 (60) 35 (43.7) 0.1
Female 60 (40) 45 (56.2)
Age
� 50 95 (63.3) 42 (52.5) 0.2
< 50 55 (36.6) 38 (47.5)
Smoking history
Current 90 (60) 29 (36.2) 0.34
Former 45 (30) 25 (31.2)
Never 15 (10) 26 (32.5)
Alcohol consumption
Non-drinker 60 (40) 20 (25) 0.09
Former drinker 60 (40) 35 (43.7)
Current drinker 30 (20) 25 (31.25)
Alcoholic & Smoking
Yes 35 (23.3) 10 (12.5) 0.5










HPV16 +ve 35 (23.3)
HPV16 -ve 25 (16.6)
HPV status missing 90 (60)
Total 150 (100)
https://doi.org/10.1371/journal.pone.0221779.t001
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(Target miRNA)]- [Ct (miR-16)], and the relative miRNA expression level were calculated as
2^-(ΔCt) which is commonly used in miRNAs detection studies. The p-value less than 0.05
was considered as significant.
Results
Characteristics of study subjects
In total, there were 150 saliva samples from HNSCC patients admitted to the GCUH and 80
saliva samples were collected from healthy matching controls, students and staff of Griffith
University. The tumour localizations, histopathological features, treatment options, and demo-
graphic properties of the HNSCC patients are listed in Table 1. The mean age of the HNSCC
patients was 60.5 ± SD years, while the mean age of the healthy controls was 56.6 ± SD years
where P = 0.2 (Table 1). The HNSCC group consisted of 90 men and 60 women, and the
healthy controls consisted of 35 men and 45 women. In addition, there were no significant dif-
ferences between these groups in terms of smoking and alcohol consumption (p = 0.09) habits.
The expression of the five candidate miRNAs from HNSCC patients and
healthy controls
Based on previous studies performed on profiling miRNAs from different samples and their
potential as targets and functions on oral cancer, five salivary miRNAs (miR-7703, miR- let-
7a-5p, miR- 345-5p, miR- 3928 and miR- 1470) were selected for further confirmation using
the RT-qPCR technique. We investigated these five validated neoplasm-associated miRNAs in
supernatant saliva from both patients with HNSCC and controls groups. Two validated miR-
NAs (miR- let-7a-5p, miR- 3928) were significantly down regulated (Fig 1). Moreover, the
other three validated miRNAs (miR-7703, miR-345-5p and miR-1470) were shown to be
slightly dysregulated (up or down), although not significant in the HNSCC group compared
with the healthy controls where p value were 0.13, 0.07, 0.09, respectively (Fig 1).
Discriminatory power of miR-let-7a-5p and miR-3928
Receiver Operator Curves (ROC) were created to evaluate the discriminatory power of miR-
let-7a-5p and miR- 3928 for their ability to distinguish between control and disease groups.
These miRNAs were revealed to provide a good discriminative ability with AUC values of
0.85and 0.74, respectively. Fig 2 shows ROC analyses for these two miRNAs using supernatant
salivary samples from all 150 HNSCC patients and 80 healthy controls. Interestingly, this
study has revealed that salivary miR-let-7a-5p was significantly influenced by cancer staging
and lymph node metastasis (Fig 3). Furthermore, a closer look at the miR-3928 in this study
showed that, in the late stage tumor group, the down-regulation of the miRNA had a signifi-
cant decrease in expression compared with first tumor stage model of patients with HNSCC
Table 2. Sequence, genomic location and primers of novel miRNAs.
miRNA Mature sequence 50–30 Forward primer Reverse Primer
miR-7703 UUGCACUCUGGCCUUCUCCCAGG TTGCACTCTGGCCTTCTCC GAACATGTCTGCGTATCTC
miR-7a-5p UGAGGUAGUAGGUUGUAUAGUU GCAGTGAGGTAGTAGGTTGT GGTCCAGTTTTTTTTTTTTTTTAACTATAC
miR-3928 UGAAGCUCUAAGGUUCCGCCUGC TGAAGCTCTAAGGTTCCGCC GAACATGTCTGCGTATCTC
miR-1470 GCCCUCCGCCCGUGCACCCCG CCTCCGCCCGTGCAC GAACATGTCTGCGTATCTC
miR-345-5p GCUGACUCCUAGUCCAGGGCUC CGCAGTACAGTACTGTGATAAC AGGTCCAGTTTTTTTTTTTTTTTCAG
miRNA-16 UAGCAGCACGUAAAUAUUGGCG AGCAGCACGTAAATATTGG GAACATGTCTGCGTATCTC
https://doi.org/10.1371/journal.pone.0221779.t002
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while no significant differences has been revealed in metastasis model of this miRNA (Fig 3).
Expression of miR- let-7a-5p and miR- 3928 on epigenetic variables such as smoking and alco-
hol consumption when compared was statistically different (p = 0.05; Table 1 and Fig 4).
Discussion
There are no saliva-based biomarkers available in the early detection or as a prognostic indica-
tor for HNSCC. We are reporting two novel biomarkers (miR- let-7a-5p and miR- 3928) in
saliva that we had identified to be a reliable with a potential to aid in the diagnosis and progno-
sis of HNSCC. This adds credibility to the existing knowledge on low level expression of miR-
let-7a and miR-3928 as well as the identified list of targeted oncogenes or suppressor genes
Fig 1. Expression of candidate miRNA in supernatant saliva of subjects (n = 150) vs. control (n = 80). (A) Significant decrease of miR-
let-7a-5p, miR-3928. (B) Expression of miR-345-5p, miR-1470 and miR-7703, p-values is indicated as follows: � p< 0.05 and ���� p< 0.001
(t test).
https://doi.org/10.1371/journal.pone.0221779.g001
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[33, 34]. This, to our knowledge, is the first report on these two salivary miRNAs in patients
with HNSCC. Another study mentioned that miR-let-7a down regulates the miR-21 expres-
sion [35], an oncogenic miRNA that was highly expressed in different types of cancer[36, 37].
Interestingly, miR-let-7a was also the most downregulated miRNA amongst others in plasma
sample of patients with colorectal cancer when compared with normal controls using
Fig 2. Receiver operator curve (ROC) analysis of the independent validation study using saliva-derived (A) miR-let-
7a-5p and (B) miR-3928.
https://doi.org/10.1371/journal.pone.0221779.g002
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qRT-PCR [38]. In addition, it has been reported by strong evidence that miR-let-7a targeted
genes in several types of cancer, for instance, CASP8, BCL2, CCND2, EWSR1, FOXA1,
DICER1, HMGA1, HMGA2, KRAS, MYC, HRAS, MPL, NF2, PRDM1, NRAS [39]34 and
COSMIC [40]. It is known that, different malignancies are initiated by dysregulation of the
p53 tumour suppressor protein. Many genes are altered in expression by p53 deregulation
which lead to cell-cycle arrest, inhibition of angiogenesis and apoptosis [41]. Zhang and col-
leagues have reported that p53 regulates different genes such as miR-let-7a, miR-34a, caspase3
and bcl2 [42].
However, cell proliferation has been inhibited by the increased level of miR-let-7a in the
cell line of pancreatic cancer [43]. Several studies have reported that let-7a could inhibit the
Fig 3. Expression of miR-let-7a-5p and miR-3928 in different groups of HNC patients (n = 150). HNC patients
were categorized according to clinical stage (T) and the presence [N+] and absence [N0] of lymph node metastasis.
Significance of two-sided p-values indicated as follows: �� p< 0.01, ���� P<0.0001 (t test).
https://doi.org/10.1371/journal.pone.0221779.g003
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growth of cells in lung cancer and lymphoma [44, 45] and STAT3 signalling was influenced by
miR-let-7a in cervical carcinogenesis.[46]. Transfection of let-7a-1 precursor miRNA lead to
inhibited expression of c-myc and RAS proteins and cause of significant suppression in
growth. [47].
We report significant down-regulation of miR-3928 in the supernatant saliva samples from
HNSCC patients. Tumour inhibition role of miR-3928 has been demonstrated in osteosar-
coma [33]. It has been reported that the expression of miR-3928 was down-regulated, and high
level of miR-3928 inhibited the growth of tumour in osteosarcoma tissue [33]. Another study
has reported that activation of phosphorylated checkpoint kinase 1 (Chk1), Rad3-related
kinase (ATR) and DNA damage are induced by upregulation of miR-3928 accompanied by G1
arrest. [28].
Recent reports confirmed that, HBX induces miR-3928v through NF-κB/EGR1 signalling
pathway and accelerated hepatocellular carcinoma by decreasing the expression of suppressor
Fig 4. Expression of miR-let-7a-5p and miR-3928 in different groups of patients (n = 150) were classified by the habit of
smoking and alcohol consumption. Significance of two-sided p-values is indicated as follows: � p< 0.05 (t test).
https://doi.org/10.1371/journal.pone.0221779.g004
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gene VDAC3 using calorimetry, colony formation, migration/invasion, vascular mimicry assays
in vitro and xenograft tumour model in vivo using hepatocellular carcinoma cell lines [48]
Conclusion
Our results concluded that the expression levels of the miR-let-7a-5p and miR-3928 were sig-
nificantly decreased in supernatant saliva samples of patients with HNSCC compared with the
healthy matched controls. Furthermore, ROC curve analysis revealed that slivery miR-let-7a-
5p and miR-3928 expression levels have significant sensitivity and specificity to differentiate
between HNSCC patients and healthy controls. This study suggests that the downregulation of
miR-let-7a-5p and miR-3928 in patients with HNSCC could be useful tool as an early diagnos-
tic aid and prognostic indicator for HNSCC. Further studies using a larger number of patients,
different sites and stages of HNSCC are necessary before elucidating the full potential of the
above two miRNAs as salivary biomarkers for HNSCC.
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